AIS1
MCID: ATM052
MIFTS: 36

Autoimmune Disease 1 (AIS1)

Categories: Genetic diseases

Aliases & Classifications for Autoimmune Disease 1

MalaCards integrated aliases for Autoimmune Disease 1:

Name: Autoimmune Disease 1 57 72 29 6
Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 2 57 72
Autoimmune Disease, Susceptibility to, 1 57 13
Autoimmune Diseases 44 70
Vamas2 57 72
Ais1 57 72
Vitiligo-Associated Multiple Autoimmune Disease Susceptibility 2; Vamas2 57
Autoimmune Disease Susceptibility Locus, Chromosome 1p-Related 57
Autoimmune Disease Susceptibility Locus Chromosome 1p-Related 72
Vitiligo-Associated Multiple Autoimmune Disease Type 2 72
Autoimmune Disease, Susceptibility to, Type 1 39
Autoimmune Disease Susceptibility 1 72

Characteristics:

OMIM®:

57 (Updated 20-May-2021)
Inheritance:
autosomal dominant

Miscellaneous:
early age at onset (13 years)


HPO:

31
autoimmune disease 1:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

OMIM® 57 607836
MeSH 44 D001327
MedGen 41 C1842979
SNOMED-CT via HPO 68 21983002 263681008 56727007
UMLS 70 C0004364

Summaries for Autoimmune Disease 1

UniProtKB/Swiss-Prot : 72 Autoimmune disease 1: An autoimmune disorder characterized by the association of vitiligo with autoimmune thyroiditis (Hashimoto thyroiditis).

MalaCards based summary : Autoimmune Disease 1, also known as vitiligo-associated multiple autoimmune disease susceptibility 2, is related to vitiligo-associated multiple autoimmune disease susceptibility 1 and autoimmune disease of the nervous system. An important gene associated with Autoimmune Disease 1 is FOXD3 (Forkhead Box D3). The drugs Sofosbuvir and Ledipasvir have been mentioned in the context of this disorder. Affiliated tissues include bone, thyroid and kidney, and related phenotypes are hashimoto thyroiditis and vitiligo

More information from OMIM: 607836

Related Diseases for Autoimmune Disease 1

Diseases related to Autoimmune Disease 1 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 981)
# Related Disease Score Top Affiliating Genes
1 vitiligo-associated multiple autoimmune disease susceptibility 1 11.3
2 autoimmune disease of the nervous system 11.2
3 pemphigus 11.1
4 celiac disease 1 11.1
5 graves' disease 11.1
6 interstitial lung disease 11.1
7 dermatomyositis 11.1
8 sjogren syndrome 11.1
9 premature menopause 11.1
10 polymyositis 11.0
11 stiff-person syndrome 11.0
12 mixed connective tissue disease 11.0
13 neuromyelitis optica 11.0
14 autoimmune disease, multisystem, infantile-onset, 1 10.9
15 cutaneous lupus erythematosus 10.9
16 adult-onset still's disease 10.9
17 scleroderma, familial progressive 10.9
18 heart block, congenital 10.9
19 autoimmune encephalitis 10.9
20 optic neuritis 10.9
21 immunoglobulin a deficiency 1 10.9
22 pemphigus foliaceus 10.9
23 lambert-eaton myasthenic syndrome 10.9
24 hypoparathyroidism 10.9
25 eosinophilic fasciitis 10.9
26 autoimmune polyendocrine syndrome, type i, with or without reversible metaphyseal dysplasia 10.9
27 membranoproliferative glomerulonephritis 10.9
28 neuromuscular disease 10.9
29 c1q deficiency 10.9
30 capillary leak syndrome 10.9
31 immune system disease 10.9
32 distal renal tubular acidosis 10.9
33 alopecia areata 1 10.8
34 bronchiectasis with or without elevated sweat chloride 1 10.8
35 complement component 2 deficiency 10.8
36 spondyloenchondrodysplasia with immune dysregulation 10.8
37 lipodystrophy, partial, acquired 10.8
38 bronchiectasis with or without elevated sweat chloride 2 10.8
39 bronchiectasis with or without elevated sweat chloride 3 10.8
40 complement component 3 deficiency, autosomal recessive 10.8
41 facial dysmorphism, immunodeficiency, livedo, and short stature 10.8
42 melioidosis 10.8
43 yao syndrome 10.8
44 selective igm deficiency disease 10.8
45 immunoglobulin beta deficiency 10.8
46 scleroperikeratitis 10.8
47 brawny scleritis 10.8
48 sclerosing keratitis 10.8
49 spinal cord disease 10.8
50 complement component 3 deficiency 10.8

Graphical network of the top 20 diseases related to Autoimmune Disease 1:



Diseases related to Autoimmune Disease 1

Symptoms & Phenotypes for Autoimmune Disease 1

Human phenotypes related to Autoimmune Disease 1:

31
# Description HPO Frequency HPO Source Accession
1 hashimoto thyroiditis 31 HP:0000872
2 vitiligo 31 HP:0001045

Symptoms via clinical synopsis from OMIM®:

57 (Updated 20-May-2021)
Skin Nails Hair Skin:
vitiligo, generalized
depigmentation, slowly progressive and diffuse

Endocrine Features:
hashimoto thyroiditis (some patients)

Clinical features from OMIM®:

607836 (Updated 20-May-2021)

Drugs & Therapeutics for Autoimmune Disease 1

Drugs for Autoimmune Disease 1 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 294)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Sofosbuvir Approved Phase 4 1190307-88-0 45375808
2
Ledipasvir Approved Phase 4 1256388-51-8 67505836
3
Mitoxantrone Approved, Investigational Phase 4 65271-80-9 4212
4
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
5
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
6
Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
7
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0
8
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
9
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
10
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
11
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
12
Thalidomide Approved, Investigational, Withdrawn Phase 4 50-35-1 5426
13
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
14
Cephalexin Approved, Investigational, Vet_approved Phase 4 15686-71-2 27447
15
Doxycycline Approved, Investigational, Vet_approved Phase 4 564-25-0 54671203
16
Calcitriol Approved, Nutraceutical Phase 4 32222-06-3 134070 5280453
17
Prednisolone hemisuccinate Experimental Phase 4 2920-86-7
18 Vasoconstrictor Agents Phase 4
19 Neuroprotective Agents Phase 4
20 Antiemetics Phase 4
21 Methylprednisolone Acetate Phase 4
22 Antineoplastic Agents, Hormonal Phase 4
23 Protective Agents Phase 4
24 Antitubercular Agents Phase 4
25 Analgesics Phase 4
26 Anti-Inflammatory Agents, Non-Steroidal Phase 4
27 Analgesics, Non-Narcotic Phase 4
28 Angiogenesis Inhibitors Phase 4
29 Complement System Proteins Phase 4
30 Complement C3 Phase 4
31 Cyclooxygenase Inhibitors Phase 4
32 Cephalosporins Phase 4
33 methicillin Phase 4
34
Methotrexate Approved Phase 3 1959-05-2, 59-05-2 126941
35
Tofacitinib Approved, Investigational Phase 3 477600-75-2
36
Levoleucovorin Approved, Investigational Phase 3 68538-85-2 149436
37
Infliximab Approved Phase 3 170277-31-3
38
Etanercept Approved, Investigational Phase 3 185243-69-0
39
Nitroglycerin Approved, Investigational Phase 3 55-63-0 4510
40
Sorafenib Approved, Investigational Phase 3 284461-73-0 216239 406563
41
tannic acid Approved Phase 3 1401-55-4
42
Benzocaine Approved, Investigational Phase 3 1994-09-7, 94-09-7 2337
43
Fludarabine Approved Phase 2, Phase 3 21679-14-1, 75607-67-9 30751
44
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
45
Abetimus Investigational Phase 3 167362-48-3
46
Molgramostim Investigational Phase 3 99283-10-0
47 Immunosuppressive Agents Phase 3
48 Antilymphocyte Serum Phase 2, Phase 3
49 Folic Acid Antagonists Phase 3
50 Vitamin B9 Phase 3

Interventional clinical trials:

(show top 50) (show all 329)
# Name Status NCT ID Phase Drugs
1 Rituximab (RTX) Therapy in Steroid Resistant Patients or Patients Relapsing After Intravenous Steroids With Active TAO Unknown status NCT02378298 Phase 4 Rituximab;Iv Methylprednisolone;peroral methylprednisolone and Methotrexate
2 A Phase 4, Open-Label Study to Investigate the Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination for 12 Weeks in Subjects With Chronic Genotype 1 and 4 HCV Infection With Autoimmune Disease Unknown status NCT02691728 Phase 4 LDV/SOF FDC
3 Calcitriol in the Treatment of Immunoglobulin A Nephropathy Unknown status NCT00862693 Phase 4 Calcitriol
4 Evaluation of Vaccination Against Influenza (Seasonal and H1N1) in Patients Presenting Systemic or Autoimmune Diseases Treated or Not With Steroids, and/or Immunosuppressant, and/or Biotherapy: an Open, Prospective Trial (MAIVAX) Completed NCT01065285 Phase 4
5 A Pilot Study of Mitoxantrone for the Treatment of Recurrent Neuromyelitis Optica (Devic's Disease) Completed NCT00304291 Phase 4 Mitoxantrone
6 Study Evaluating Rapid Infusion Rituximab in Patients With Autoimmune Diseases Completed NCT02040116 Phase 4 Rituximab Infusion
7 Everolimus in Association With Very Low-dose Tacrolimus Versus Enteric-coated Mycophenolate Sodium With Low-dose Tacrolimus in de Novo Renal Transplant Recipients - A Prospective Single Center Study Completed NCT02084446 Phase 4 Everolimus;Very Low Tacrolimus;Low Tacrolimus;Steroids;Thymoglobulin;Sodium Mycophenolate
8 A Placebo Controlled Trial of Amoxicillin for Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections Completed NCT00001658 Phase 4 Amoxicillin
9 Immune Response After Human Papillomavirus Vaccination in Patients With Autoimmune Disease Completed NCT00815282 Phase 4
10 Influence of Plasma Exchange Therapy on the Pharmacokinetics of Rituximab in Patients Treated for Autoimmune Disorders. Completed NCT00820469 Phase 4 Rituximab 375;rituximab 1000
11 Relevance of Monitoring Blood Levels Compared to Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases: Adherence and Understanding the Possible Underlying Mechanisms Involved in Effectiveness and in Adverse Effects Recruiting NCT03122431 Phase 4 Thalidomide;Hydroxychloroquine reduced;Hydroxychloroquine high
12 Patient-Reported AutoImmunity Secondary to Cancer immunothErapy Recruiting NCT03849131 Phase 4
13 A Multicenter, Randomized Controlled Clinical Study About Efficacy and Safety of Standard Dose and Individualized Dose of Rituximab in Maintaining Remission in Patients With Moderate to Severe Systemic Lupus Erythematosus Recruiting NCT04127747 Phase 4 Standard dose of rituximab;Individualized dose of rituximab
14 Double-Blind, Randomized, Placebo-Controlled Trial of Naproxen Sodium for the Treatment of Obsessive Compulsive Symptoms in Pediatric Autoimmune Neuropsychiatric Disorder Associated With Streptococcal Infections (PANDAS) Recruiting NCT04015596 Phase 4 Naproxen Sodium
15 Antibiotic Prophylaxis in High-Risk Arthroplasty Patients Not yet recruiting NCT04297592 Phase 4 Cephalexin Oral Tablet;Doxycycline Hyclate
16 Exploring the Effects of IL-23 Inhibition by Risankizumab on Psoriasis Autoimmunity Not yet recruiting NCT04722640 Phase 4 SKYRIZI
17 Hydroxychloroquine in SARS-CoV-2 (COVID-19) Pneumonia Trial Withdrawn NCT04382625 Phase 4 Hydroxychloroquine
18 Clinical and Immunological Long-term Follow-up of Patients With Pemphigus Included in the "RITUXIMAB 3" Trial With Medico-economic Evaluation of the Treatment. Unknown status NCT03790293 Phase 3 Rituximab;corticosteroids'therapy
19 A Study of a Topical Formulation of Nitroglycerin, MQX-503, and Matching Vehicle in the Treatment and Prevention of Raynaud's Phenomenon Unknown status NCT00577304 Phase 3 Nitroglycerin;Topical AmphiMatrix
20 Phase 3 Randomized, Double-blind Study Of The Efficacy And Safety Of 2 Doses Of Cp-690,550 Compared To Methotrexate In Methotrexate Navie Patients With Rheumatoid Arthritis Completed NCT01039688 Phase 3 CP-690,550;CP-690,550;Disease-modifying antirheumatic drug
21 Measurement and Analysis of Patient Reported Gastrointestinal (GI) and Health-related Quality of Life (HRQL) Outcomes in Patients With Autoimmune Diseases Treated With Mycophenolate (MPA) Completed NCT00351377 Phase 3 Enteric-coated Mycophenolate Sodium
22 Evaluation of Therapeutic Plasma Exchange (TPE) Procedure Using the AMICUS Device Completed NCT01210716 Phase 3
23 Phase 3 Study of Hydroxychloroquine Treatment of Dry Eyes in Patients With Primary Sjögren's Syndrome Completed NCT01601028 Phase 3 Hydroxychloroquine;Placebo
24 Childhood Onset Psychiatric Disorders: A Placebo Controlled Double-Blind Crossover Trial of Intravenous Immunoglobulin (IVIg) Completed NCT00001768 Phase 3 Intravenous immunoglobulin
25 Immunogenicity and Duration of Immunity in Immunosuppressed Children Vaccinated With Quadrivalent HPV Vaccine Completed NCT02263703 Phase 3
26 A Randomised, Double-Blind, Placebo-Controlled Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary AlveoLAr Proteinosis Patients "IMPALA" Completed NCT02702180 Phase 2, Phase 3 molgramostim;placebo
27 A Placebo-Controlled Trial of Intravenous Immunoglobulin (IVIG) for PANDAS (Pediatric Autoimmune Neuropsychiatric Disorders Associated With Streptococcal Infections) Completed NCT01281969 Phase 3 Gamunex Intravenous Immunoglobulin;Placebo
28 A Phase 3, Multicenter, Randomized, Double-blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Patients With Systemic Lupus Erythematosus (SLE) Completed NCT01205438 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks
29 An Open-label, Non-controlled, Multicentre Clinical Trial of Inhaled Molgramostim in Autoimmune Pulmonary Alveolar Proteinosis Patients Completed NCT03482752 Phase 3 Molgramostim
30 A Golimumab Phase 3b, Multicenter, Switch Assessment of Subcutaneous and Intravenous Efficacy in Rheumatoid Arthritis Patients Who Have Inadequate Disease Control Despite Treatment With Etanercept (ENBREL) or Adalimumab (HUMIRA) Completed NCT01004432 Phase 3 Golimumab 50 mg SC;Golimumab 2 mg/kg IV;Methotrexate (MTX);Placebo SC;Placebo IV
31 Double-Blind, Parallel-group Comparison, Investigators Initiated Phase II Clinical Trial of IDEC-C2B8 (Rituximab) in Patients With Systemic Sclerosis Completed NCT04274257 Phase 2, Phase 3 Double-Blind Placebo;Double-Blind Rituximab
32 A Phase 3, Multicenter, Randomized, Double Blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) Completed NCT01196091 Phase 3 LY2127399;Placebo every 2 weeks;Placebo every 4 weeks;Standard of Care
33 Phase III "In-Life" Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, and Matching Placebo Gel in the Treatment and Prevention of Raynaud's Phenomenon Completed NCT00419419 Phase 3 Topical AmphiMatrix with nitroglycerin (MQX-503)
34 Phase III Laboratory Study of a Topical Gel Formulation of Nitroglycerin, MQX-503, in the Treatment of Raynaud's Phenomenon Completed NCT00253331 Phase 2, Phase 3 topical organogel with nitroglycerin
35 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease Completed NCT00035308 Phase 3 Abetimus sodium (LJP 394)
36 A Randomized, Open-Label, Phase II Multicenter Study of High-Dose Immunosuppressive Therapy Using Total Body Irradiation, Cyclophosphamide, ATGAM, and Autologous Transplantation With Auto-CD34+HPC Versus Intravenous Pulse Cyclophosphamide for the Treatment of Severe Systemic Sclerosis (SCSSc-01) Completed NCT00114530 Phase 2, Phase 3 cyclophosphamide
37 Study on Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer Recruiting NCT04163237 Phase 3 PD-1;Sorafenib
38 COVID-19 Vaccine in Immunosuppressed Adults With Autoimmune Diseases Recruiting NCT04806113 Phase 3
39 A Randomized, Double-blind, Placebo-controlled Clinical Trial of Once-daily Inhaled Molgramostim Nebulizer Solution in Adult Subjects With Autoimmune Pulmonary Alveolar Proteinosis (aPAP) Not yet recruiting NCT04544293 Phase 3 Molgramostim;Placebo
40 Autologous Hematopoietic Stem Cell Transplant for Patients With Systemic Sclerosis and Cardiac Dysfunction Terminated NCT03593902 Phase 2, Phase 3 Rituximab;Fludarabine;Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF
41 Will Hydroxychloroquine Impede or Prevent COVID-19: WHIP COVID-19 Study Terminated NCT04341441 Phase 3 Hydroxychloroquine - Daily Dosing;Hydroxychloroquine - Weekly Dosing
42 A Phase 3b, Multicenter, Open-Label Study to Evaluate the Long-Term Safety and Efficacy of Subcutaneous LY2127399 in Participants With Systemic Lupus Erythematosus (SLE) (Illuminate-X) Terminated NCT01488708 Phase 3 LY2127399;Placebo
43 Autologous Hematopoietic Stem Cell Transplant for Neuromyelitis Optica Spectrum Disorder (NMOSD) Withdrawn NCT03829566 Phase 2, Phase 3 Rituximab;Cyclophosphamide;Mesna;rATG;Methylprednisolone;G-CSF
44 Phase I/II Open-Label Monocentric Clinical Trial for Induction of Tolerance With CD34-Enriched Autologous Hematopoietic Stem Cell Transplantation After High-Dose Chemotherapy With Cyclophosphamide and Rabbit-Antithymocyte Globulin for Refractory Autoimmune Diseases Unknown status NCT00742300 Phase 1, Phase 2
45 Phase 1 Clinical Trial Using Regulatory T Cells as Individualized Medicine to Evaluate the Safety and Efficacy in Autoimmune Hepatitis Unknown status NCT02704338 Phase 1, Phase 2
46 A Randomized Trial of Treatment in Patients With IgG4-Related Disease Unknown status NCT02458196 Phase 2 Prednisone;Prednisone and Mycophenolate mofetil
47 Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. Unknown status NCT01579110 Phase 2 levamisole;Prednisone
48 A Phase 2 Randomized, Double-blind, Placebo-controlled Study in HLA-DQ2.5+ Adults With Celiac Disease to Assess the Effect of Nexvax2 on Symptoms After Masked Gluten Food Challenge Unknown status NCT03644069 Phase 2
49 Mesenchymal Stem Cell Therapy for the Treatment of Severe or Refractory Inflammatory and/or Autoimmune Disorders Unknown status NCT01540292 Phase 1, Phase 2
50 A Prospective Study of Inhaling Granulocyte-macrophage Colony Stimulating Factor in Adult Patients With Mild-to-moderate Autoimmune Pulmonary Alveolar Proteinosis in China: a Randomized Open-label Study Unknown status NCT02243228 Phase 2 GM-CSF

Search NIH Clinical Center for Autoimmune Disease 1

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Methylprednisolone
methylprednisolone acetate
Methylprednisolone Sodium Succinate
Prednisone
PREDNISONE PWDR

Cochrane evidence based reviews: autoimmune diseases

Genetic Tests for Autoimmune Disease 1

Genetic tests related to Autoimmune Disease 1:

# Genetic test Affiliating Genes
1 Autoimmune Disease 1 29 FOXD3

Anatomical Context for Autoimmune Disease 1

MalaCards organs/tissues related to Autoimmune Disease 1:

40
Bone, Thyroid, Kidney, Eye, Liver, Heart, Bone Marrow

Publications for Autoimmune Disease 1

Articles related to Autoimmune Disease 1:

(show all 26)
# Title Authors PMID Year
1
Candidate functional promoter variant in the FOXD3 melanoblast developmental regulator gene in autosomal dominant vitiligo. 57 6
16098053 2005
2
A genomewide screen for generalized vitiligo: confirmation of AIS1 on chromosome 1p31 and evidence for additional susceptibility loci. 61 57
12707860 2003
3
Mapping of an autoimmunity susceptibility locus (AIS1) to chromosome 1p31.3-p32.2. 57 61
11912181 2002
4
Mapping the major susceptibility loci for familial Graves' and Hashimoto's diseases: evidence for genetic heterogeneity and gene interactions. 57
10599734 1999
5
A 6-year survey of road traffic accidents in Southwest China: Emphasis on traumatic brain injury. 61
32563388 2020
6
Far Side Impact Injury Threshold Recommendations Based on 6 Paired WorldSID / Post-Mortem Human Subjects Tests. 61
32311054 2019
7
Characteristics of pedestrian head injuries observed from real world collision data. 61
31130209 2019
8
Genomics-Driven Immunoproteomics: An Integrative Platform to Uncover Important Biomarkers for Human Diseases. 61
31364060 2019
9
Immune mediated conditions in autism spectrum disorders. 61
25681541 2015
10
[INDICATIONS FOR ANTITHROMBOTIC MEDICATION DURING PREGNANCY--ANALYSIS OF CURRENT PRACTICES IN BULGARIA]. 61
26411189 2015
11
Airway management and endoscopic treatment of subglottic and tracheal stenosis: the laryngeal mask airway technique. 61
24671485 2014
12
Bicycle helmet wearing and the risk of head, face, and neck injury: a French case--control study based on a road trauma registry. 61
21606469 2012
13
[II. Autoimmune disease: 1. Systemic lupus erythematosus]. 61
21702138 2011
14
Unusual association between adrenal leiomyoma and autoimmune disease. 61
20174739 2010
15
Collagenous gastritis: histopathologic features and association with other gastrointestinal diseases. 61
19295410 2009
16
Biosynthesis of t-anethole in anise: characterization of t-anol/isoeugenol synthase and an O-methyltransferase specific for a C7-C8 propenyl side chain. 61
18987218 2009
17
Risk of permanent medical impairment (RPMI) in road traffic accidents. 61
19026226 2008
18
Minor crashes and 'whiplash' in the United States. 61
19026229 2008
19
Evidence for two susceptibility loci on chromosomes 22q12 and 6p21-p22 in Chinese generalized vitiligo families. 61
17568780 2007
20
Motor vehicle restraint system use and risk of spine injury. 61
16990240 2006
21
The first three years of the Swiss Neuropaediatric Stroke Registry (SNPSR): a population-based study of incidence, symptoms and risk factors. 61
15822021 2005
22
A Study of AIS1 Neck Injury Parameters in 168 Frontal Collisions Using a Restrained Hybrid III Dummy. 61
17458721 2000
23
Influence of Airbags and Seatbelt Pretensioners on AIS1 Neck Injuries for Belted Occupants in Frontal Impacts. 61
17458722 2000
24
Neck injuries in frontal impacts: influence of crash pulse characteristics on injury risk. 61
10688476 2000
25
CNS vasculitis in autoimmune disease: MR imaging findings and correlation with angiography. 61
9974060 1999
26
[Aortic valve replacement using aortic donor valves of human origin]. 61
8145864 1994

Variations for Autoimmune Disease 1

ClinVar genetic disease variations for Autoimmune Disease 1:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 FOXD3 FOXD3, -639G-T SNV risk factor 889 GRCh37:
GRCh38:

Expression for Autoimmune Disease 1

Search GEO for disease gene expression data for Autoimmune Disease 1.

Pathways for Autoimmune Disease 1

GO Terms for Autoimmune Disease 1

Sources for Autoimmune Disease 1

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....